Philips introduces first at-home, 12-lead ECG integrated solution for decentralized clinical trials
January 26 2022 - 4:00AM
Philips introduces first at-home, 12-lead ECG integrated solution
for decentralized clinical trials
January 26, 2022
Philips expands remote cardiac monitoring portfolio with
patch-based, clinical-grade ECG designed to improve patient
recruitment, compliance and retention by reducing need for site
visits during clinical trials
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced the introduction of the industry’s first full-service,
at-home, 12-lead electrocardiogram (ECG) solution for use in
decentralized clinical trials. The clinical-grade solution is the
most advanced patient-centric ECG offering within the company’s
cardiac monitoring portfolio, pairing data readings comparable to
clinical, site-based ECGs with Philips leading cloud-based data
collection and analysis services. This latest addition to Philips’
digitally enabled suite of monitoring solutions helps to drive
innovation across the care continuum and support the decentralized
clinical trial space.
Patient attrition is one of the biggest issues faced by clinical
trial sponsors seeking regulatory approval for new therapies.
Attrition over the course of a study can reduce the quality of its
findings and can lead to longer, more expensive trials that require
higher than optimal recruiting rates to compensate. Voluntary
patient withdrawal is often tied to disease progression or the
prolonged inconvenience of adhering to protocol regimens and
repetitive site visits [1]. By offering the consistent and reliable
standards of a 12-lead ECG in the comfort and convenience of a
patient’s home, Philips at-home ECG solution aims to improve trial
recruitment, compliance and patient retention by reducing the need
for and burden of site visits.
“Our customers are seeking solutions that will help them to
address key challenges that can stand in the way of extracting
meaningful insights from their clinical trials,” said Andy
Broadway, General Manager of Ambulatory Monitoring and Diagnostics
at Philips. “Our growing portfolio of remote monitoring solutions
help to curb patient attrition by reducing the amount of site
visits required during the trial period, helping to improve both
the quality of the outcome and the patient experience overall.”
Leveraging PCA 500 ECG patch data recording technology, the
at-home solution allows clinical trial participants to record data
with quality comparable to site-based ECGs at home. The solution’s
innovative body-worn patch ensures compliant 12-lead ECG placement
and near real-time, highly secure data transmission without the
need for recurring site visits, onsite technician, or home
nurses.
Philips offers a complete range of clinically validated
ambulatory cardiac diagnostics and monitoring services and
associated expertise to its cardiac care portfolio, including its
BioTel Research capabilities that have already supported more than
2,000 clinical trials in 72 countries. These comprehensive
offerings provide industry-leading technology and data management
that streamlines the clinical trials process and ensures optimal
performance. The at-home, 12-lead ECG solution is now available in
select markets across North America, Europe and Asia.
[1] Hui D, Glitza I, Chisholm G, Yennu S, Bruera E. Attrition
rates, reasons, and predictive factors in supportive care and
palliative oncology clinical trials. Cancer. 2013;119(5):1098-1105.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568443/
For further information, please contact:
Meredith AmorosoPhilips Global Press OfficeTel: +1
724-584-8991E-mail: meredith.amoroso@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being, and enabling better outcomes across the health
continuum – from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2021 sales of EUR 17.2 billion and
employs approximately 78,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
- Philips introduces first at-home, 12 lead ECG integrated
solution for decentralized clinical trials
- Philips new at-home, 12 lead ECG solution helps to reduce need
for site visits during clinical trials
Koninklijke Philips NV (BIT:1PHIA)
Historical Stock Chart
From Apr 2024 to May 2024
Koninklijke Philips NV (BIT:1PHIA)
Historical Stock Chart
From May 2023 to May 2024